Cardiovascular/metabolic companies are NormOxys (OXY 111A for hypoxia), Spherix (Tagatose for Type 2 diabetes mellitus), Resverlogix Corp. (RVX 208 for Acute coronary syndromes, Alzheimer's disease, Atherosclerosis), Genfit (GFT 505 for lipid metabolism disorders), Halozyme Therapeutics (Hyaluronidase/insulin), Lexicon Pharmaceuticals (LX4211 for Type 2 diabetes), Rhythm (RM-493 for obesity and insulin resistance), Momenta Pharmaceuticals (M 118 for acute coronary syndromes), Viron Therapeutics (VT 111 for Acute coronary syndromes, Atherosclerosis, Coronary artery restenosis, Myocardial reperfusion injury, Rheumatoid arthritis, Transplant rejection) and Stealth Peptides (MTP131 for Myocardial infarction and aschemia reperfusion injury).
Companies with top infectious diseases projects are Progenics Pharmaceuticals Inc. ) PRO 140 for HIV/AIDS), Vaxinnate (VAX125 for flu), SCYNEXIS Inc. (SCY-635 for Hepatitis C), GlobeImmune Inc. (GI-5005 for Hepatitis C), Optimer Pharma (Fiaxomicin, antibiotic), Sangamo Biosciences (SB-728-T for HIV/AIDS), Achillion (ACH-1625 for HCV), Theravance (TD-1792 for MRSA), Argos Therapeutics (AGS-004 for HIV/AIDS) and Dynavax (HEPLISAV for hepatitis B).
Woohoo! Three of my eight holdings are presenting at this conference. I imagine I shouldn't break out the bubbly just yet. Seriously though, is this a well-respected conference?